Assessing the impact of the addition of dendritic cell vaccination to neoadjuvant chemotherapy in breast cancer patients: A model-based characterization approach.
CONCLUSIONS: Dendritic Cell-based immunotherapy is effective in decreasing tumour size. The semi-mechanistic validated model presented allows the quantification of the immunotherapy treatment effects on tumour shrinkage and establishes the relationship between the dynamics of tumour size and PFS.
PMID: 30933365 [PubMed - as supplied by publisher]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: P Solans B, López-Díaz de Cerio A, Elizalde A, Pina LJ, Inogés S, Espinós J, Salgado E, Mejías LD, Trocóniz IF, Santisteban M Tags: Br J Clin Pharmacol Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cancer Vaccines | Chemotherapy | HER2 | Immunotherapy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Vaccines